Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings Routine +

Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering

By The Northwire Desk — AI Analysis Apr 13, 2026 · 17:31 MRVL · 0.165 Marvel Biosciences Corp.
MRVL · Price

Executive Summary

  • Marvel Biosciences Corp. has amended the conversion price for its previously announced non-brokered private placement of unsecured convertible debentures.

Key Details

  • Instrument: Unsecured convertible debentures.
  • Principal Amount: Up to $500,000.
  • Amended Conversion Price: $0.17 per Common Share.
  • Status: The offering remains subject to approval by the TSX Venture Exchange.
  • Other Terms: All other terms of the debentures and the offering remain unchanged from the announcement made on April 8, 2026.
Read the original news release →

More from Marvel Biosciences Corp.

Jun 08, 2026 · 07:00

Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

M&A / Property Apr 23, 2026 · 07:30

Marvel Biosciences Secures Funding and Patent Protection for Phase 1 Neurodevelopmental Candidate MB-204

Other Apr 17, 2026 · 16:30

Marvel Biosciences Closes Financing to Fuel Phase I Transition Amidst Patent Wins

Financings Apr 16, 2026 · 07:00

Marvel Biosciences Advances MB-204 Formulation Ahead of Phase I, But Data Integrity Concerns Linger

Other Apr 08, 2026 · 16:31

Small convertible debenture adds cash but raises dilution risk amid mounting debt

Financings Apr 07, 2026 · 07:30

New strategic financing trims Phase I cash burn, nudging MB‑204 toward first‑in‑human trial

Financings